PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för TA-1887. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

8 hits

Bibliografisk träff 2023-12-06

Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter.

Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, Nureki O, Miyaguchi I.

Nat Struct Mol Biol · research-article; journal article · DOI 10.1038/s41594-023-01134-0

Bibliografisk träff 2022-03-09

Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.

Shimada K, Kanasaki K, Kato M, Ogura Y, Takagaki Y, Monno I, Hirai T, Kitada M, Koya D.

J Diabetes Investig · research-article; journal article · DOI 10.1111/jdi.13760

Bibliografisk träff 2017-10-28

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats.

Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, Hitomi H, Kobori H, Nishiyama A.

J Pharmacol Sci · research-article; journal article · DOI 10.1016/j.jphs.2017.10.006

Bibliografisk träff 2017-09-08

Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality.

Sugizaki T, Zhu S, Guo G, Matsumoto A, Zhao J, Endo M, Horiguchi H, Morinaga J, Tian Z, Kadomatsu T, Miyata K, Itoh H, Oike Y.

NPJ Aging Mech Dis · research-article; journal article · DOI 10.1038/s41514-017-0012-0

Bibliografisk träff 2017-02-14

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D'Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, Levi M.

J Biol Chem · research-article; journal article · DOI 10.1074/jbc.m117.779520

Bibliografisk träff 2016-10-28

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.

Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Hikida K, Tsuda-Tsukimoto M, Saito A, Arakawa K, Ueta K, Minami M, Shiotani M.

J Pharmacol Sci · journal article · DOI 10.1016/j.jphs.2016.10.006

Bibliografisk träff 2013-11-13

Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes.

Nomura S, Yamamoto Y, Matsumura Y, Ohba K, Sakamaki S, Kimata H, Nakayama K, Kuriyama C, Matsushita Y, Ueta K, Tsuda-Tsukimoto M.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml400339b

Bibliografisk träff 2010-11-19

Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening.

Wu JS, Peng YH, Wu JM, Hsieh CJ, Wu SH, Coumar MS, Song JS, Lee JC, Tsai CH, Chen CT, Liu YW, Chao YS, Wu SY.

J Med Chem · journal article · DOI 10.1021/jm101080v